University of Notre Dame DU Lac decreased its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 13.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,144 shares of the biopharmaceutical company’s stock after selling 4,792 shares during the period. University of Notre Dame DU Lac owned approximately 0.08% of Sage Therapeutics worth $1,878,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Sage Therapeutics by 11.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 138 shares during the period. Hershey Trust Co. acquired a new position in Sage Therapeutics during the 3rd quarter worth approximately $118,000. Bessemer Group Inc. acquired a new position in Sage Therapeutics during the 3rd quarter worth approximately $141,000. Turner Investments LLC acquired a new position in Sage Therapeutics during the 2nd quarter worth approximately $159,000. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Sage Therapeutics during the 2nd quarter worth approximately $175,000. Institutional investors own 95.40% of the company’s stock.
Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) opened at $89.79 on Wednesday. Sage Therapeutics, Inc. has a 52 week low of $44.55 and a 52 week high of $100.50.
Several equities research analysts have recently commented on SAGE shares. Stifel Nicolaus started coverage on Sage Therapeutics in a research note on Wednesday, August 9th. They set a “buy” rating and a $104.00 price target on the stock. BidaskClub lowered Sage Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd. J P Morgan Chase & Co reissued a “buy” rating on shares of Sage Therapeutics in a research note on Thursday, August 31st. Cowen decreased their price target on Sage Therapeutics from $100.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, September 12th. Finally, Canaccord Genuity decreased their price target on Sage Therapeutics from $110.00 to $81.00 and set a “buy” rating on the stock in a research note on Tuesday, September 12th. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $105.14.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://stocknewstimes.com/2017/12/06/sage-therapeutics-inc-sage-holdings-cut-by-university-of-notre-dame-du-lac.html.
About Sage Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sage Therapeutics, Inc. (NASDAQ:SAGE).
Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.